Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting With FDA On NXC-201 U.S. Clinical Trial
Portfolio Pulse from Happy Mohamed
Immix Biopharma subsidiary Nexcella has completed a Pre-IND meeting with the FDA for NXC-201, a BCMA-targeted CAR-T cell therapy for relapsed/refractory multiple myeloma and AL amyloidosis. The FDA provided guidance and recommendations for the development plan of NXC-201.
June 26, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma's subsidiary Nexcella completed a Pre-IND meeting with the FDA for NXC-201, a CAR-T cell therapy for multiple myeloma and AL amyloidosis, receiving guidance and recommendations.
The completion of the Pre-IND meeting with the FDA is a significant milestone for Immix Biopharma and its subsidiary Nexcella. The FDA's guidance and recommendations will help the company proceed with submitting a US IND application for NXC-201, potentially leading to the opening of US clinical trial sites. This progress in the development of NXC-201 is likely to have a positive short-term impact on Immix Biopharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100